Champions Oncology Inc (CSBR) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Champions Oncology Inc.
|Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
CSBR's average price target has moved up $1.17 over the prior 27 weeks.
Over the past 27 weeks, CSBR's average upside potential has been 48.17%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
CSBR Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for CSBR as an investment opportunity.
- Champions Oncology Inc's variance in analysts' estimates is less than 81.17% of Pharmaceutical Products stocks.
- The number of analysts covering the stock of CSBR is greater than 23.4% of Pharmaceutical Products stocks.
- CSBR has a higher upside potential (average analyst target price relative to current price) than 26.53% of Pharmaceutical Products stocks.
- The average analyst price target of CSBR is greater than 28.43% of all US stocks.
In the Pharmaceutical Products industry, LYEL, JANX and ALIM are the three stocks most similar to Champions Oncology Inc regarding the price target and analyst recommendation information presented here.
What is the outlook for CSBR? Use POWR Ratings for clearer insight into price direction.